Patent: 6,566,395
✉ Email this page to a colleague
Summary for Patent: 6,566,395
Title: | Methods of treating proliferative disorders |
Abstract: | Disclosed are methods and compositions for treating proliferative disorders, such as cancers, blood vessel disorders, fibrotic disorders and acute or chronic rejection of transplanted organs, tissue or cells, using compounds of formula I or a tautomeric isomer thereof: ##STR1## wherein R.sup.1 and R.sup.2 are as defined; or a pharmaceutically-acceptable salt or pro-drug thereof. |
Inventor(s): | Moran; Stanford Mark (Orinda, CA) |
Assignee: | BioMedicines, Inc. (Alameda, CA) |
Application Number: | 09/577,689 |
Patent Claims: | see list of patent claims |
Details for Patent 6,566,395
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2019-05-25 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2019-05-25 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2019-05-25 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2019-05-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |